The effect of surgical and non-surgical weight loss on N-terminal pro-B-type natriuretic peptide and its relation to obstructive sleep apnea and pulmonary function

What Was Tested

The paper reports a study of BNP (Nesiritide) in the context of sleep apnea (obstructive), published as a controlled clinical trial.

In subjects with severe obesity undergoing weight loss treatment, the researchers assessed the associations between changes in severity of obstructive sleep apnea, pulmonary function and serum NT-proBNP levels.

Who Took Part

By PubMed's age tags, the people studied were adults, both men and women.

The reference group included 30 normal weight, healthy, gender and age matched controls.

How the Study Was Run

One-year non-randomized controlled clinical trial.

Sleep recordings, arterial blood gases, pulmonary function and blood tests were assessed before and 1 year after the interventions.

What Was Measured

In subjects with severe obesity undergoing weight loss treatment, the researchers assessed the associations between changes in severity of obstructive sleep apnea, pulmonary function and serum NT-proBNP levels.

The subject headings attached to it are Body Mass Index, Gastric Bypass, Life Style, Lung, Natriuretic Peptide, Brain, Peptide Fragments and Respiratory Function Tests.

The authors tagged it with the keywords Natriuretic peptides, Obesity, Respiration and Sleep apnea.

What This Means in Plain Language

This is a controlled clinical trial of BNP (Nesiritide) in people with sleep apnea (obstructive).

Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2016 (BMC research notes), a journal based in England.

More context: the BNP (Nesiritide) compound page, Sleep apnea (obstructive) research.